Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women's Cancers
This study is currently recruiting participants.
Verified June 2012
by National Institutes of Health Clinical Center (CC)
Study NCT01237067 Information provided by National Institutes of Health Clinical Center (CC)
First Received on November 6, 2010. Last Updated on May 1, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Mixed Muellerian Cancer
Cervical Cancer
Ovarian Cancer
Breast Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer
Endometrial Cancer
Carcinosarcoma
Additional conditions recognized in this trial
Adenoma
Breast Neoplasms
Endometrial Neoplasms
Fallopian Tube Neoplasms
Mixed Tumor, Mullerian
Ovarian Neoplasms
Peritoneal Neoplasms
Uterine Cervical Neoplasms
More general conditions related to this trial
Abdominal Neoplasms
Adnexal Diseases
Breast Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Fallopian Tube Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Complex and Mixed
Neoplasms, Connective and Soft Tissue
Neoplasms, Glandular and Epithelial
Ovarian Diseases
Peritoneal Diseases
Sarcoma
Skin Diseases
Urogenital Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Uterine Neoplasms
Interventions listed in this trial
Carboplatin
Olaparib
Treatment Effect
More general drug interventions related to this trial
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content
